Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Insomnia treatment approved for longer use

  • Comment

The indication for the prolonged release melatonin product Circadin has been extended to up to 13 weeks in patients with primary insomnia.

Circadin was previously available as a three week course of treatment, but is now approved for longer use in patients with primary insomnia, aged 55 years or over.

It is intended to help restore natural sleep rhythm by increasing levels of melatonin.

Nursing Times Learning

Online training units, written and reviewed by experts. Earn two hours’ CPD and a personalised certificate for your portfolio.

Subscribers get five FREE learning units and non-subscribers can access each learning unit for £10 + VAT.

Click on the topics below to get started:

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.